Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lifted by Mission Creek Capital Partners Inc.

Mission Creek Capital Partners Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,439 shares of the biopharmaceutical company’s stock after acquiring an additional 28 shares during the quarter. Mission Creek Capital Partners Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,513,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Finally, Family Firm Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on REGN. Oppenheimer dropped their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $749.57 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The company has a market cap of $82.37 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.94 and a beta of 0.08. The business’s 50 day moving average is $893.12 and its two-hundred day moving average is $1,016.56. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.